ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 8,400 shares, a drop of 8.7% from the September 15th total of 9,200 shares. Based on an average daily volume of 13,900 shares, the short-interest ratio is currently 0.6 days.

ProShares Ultra Nasdaq Biotechnology Trading Up 0.8 %

Shares of NASDAQ BIB traded up $0.49 during trading on Tuesday, reaching $64.40. The stock had a trading volume of 6,154 shares, compared to its average volume of 24,826. ProShares Ultra Nasdaq Biotechnology has a fifty-two week low of $40.10 and a fifty-two week high of $69.56. The business’s 50-day moving average price is $64.34 and its 200-day moving average price is $60.11.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The company also recently announced a dividend, which was paid on Wednesday, October 2nd. Shareholders of record on Wednesday, September 25th were given a $0.1528 dividend. This is an increase from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.04. The ex-dividend date was Wednesday, September 25th.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Hedge funds have recently made changes to their positions in the business. Toth Financial Advisory Corp raised its stake in shares of ProShares Ultra Nasdaq Biotechnology by 132.3% in the first quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock valued at $1,502,000 after acquiring an additional 14,870 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the 1st quarter valued at about $288,000. Finally, Westwood Wealth Management acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the 1st quarter valued at about $575,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.